Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

Bolli, Niccolo, Avet-Loiseau, Hervé, Wedge, David C., Van Loo, Peter, Alexandrov, Ludmil B., Martincorena, Inigo, Dawson, Kevin J., Iorio, Francesco +27 more·2014·Nature Communications
DOI 10.1038/ncomms3997

Cited by (875)

Items 401–500 of 875

  1. Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma
    Alessandro Allegra, Gabriella Cancemi, Giuseppe Mirabile, Alessandro Tonacci, Caterina Musolino, Sebastiano Gangemi · 2022 · Cancers
  2. Plasma Cell Tumors
    Noopur S Raje, Teru Hideshima, Andrew Jenho Yee, Kenneth Carl Anderson · 2017 · Wiley eBooks
  3. The Role of Epigenetics in the Development and Progression of Multiple Myeloma
    Ismail, Nor Hayati, Mussa, Ali, Zakaria, Nur Atikah, Al-Khreisat, Mutaz Jamal, Zahidin, Muhamad Aidil, Ramli, Noor Nabila, Mohammad, Siti Nur Nabeela A’ifah, Hassan, Rosline, Mohd Noor, Noor Haslina, Iberahim, Salfarina et al. · 2022 · Biomedicines
  4. Current concepts and future directions for hemato-oncologic diagnostics
    Johanna Flach, Evgenii Shumilov, Raphael Joncourt, Naomi Azur Porret, Urban Novak, Thomas Pabst, Ulrike Bacher · 2020 · Critical Reviews in Oncology/Hematology
  5. The Molecular Pathogenesis of Multiple Myeloma
    Niccolò Bolli, Giovanni Martinelli, Claudio Cerchione · 2020 · Hematology Reports
  6. The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability
    J. Derrien, C. Guérin-Charbonnel, Victor Gaborit, L. Campion, Magali Devic, Elise Douillard, N. Roi, H. Avet-Loiseau, O. Decaux, T. Facon et al. · 2020 · Genome Medicine
  7. WITHDRAWN: Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas
    Xiaofan Ding, Mian He, Anthony W.H. Chan, Qi Xiu Song, Siu Ching Sze, Hui Chen, K Man, Kwan Man, Stephen Lam Chan, Paul B.S. Lai et al. · 2020 · Gastroenterology · Retracted
  8. AATF/Che‐1 localizes to paraspeckles and suppresses R‐loops accumulation and interferon activation in Multiple Myeloma
    Tiziana Bruno, Giacomo Corleone, Clelia Cortile, Francesca De Nicola, Valeria Catena, Francesca Fabretti, Svitlana Gumenyuk, Francesco Pisani, Andrea Mengarelli, Claudio Passananti et al. · 2022 · The EMBO Journal
  9. Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
    Sabrina Kraus, Philipp Klassen, Malte Kircher, Alexander Dierks, Stefan Habringer, Alexander Gäble, Klaus Martin Kortüm, Niels Weinhold, Valëza Ademaj-Kospiri, Rudolf Alexander Werner et al. · 2022 · Theranostics
  10. Crosstalk between microRNA30a/b/c/d/e-5p and the Canonical Wnt Pathway: Implications for Multiple Myeloma therapy
    Jianjun Zhao, Ruben D. Carrasco · 2014 · Cancer Research
  11. Ultrasensitive and high-efficiency screen of de novo low-frequency mutations by o2n-seq
    Kaile Wang, Shujuan Lai, Xiaoxu Yang, Tianqi Zhu, Xuemei Lu, Chung‐I Wu, Jue Ruan · 2017 · Nature Communications
  12. Overexpressing miR‑335 inhibits DU145 cell proliferation by targeting early growth response 3 in prostate cancer
    Peng Zhang, Xiaojie Yang, Li Wang, Dong Zhang, Qidong Luo, Binxian Wang · 2019 · International Journal of Oncology
  13. Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells
    Jo Kanasugi, Ichiro Hanamura, Akinobu Ota, Sivasundaram Karnan, Vu Quang Lam, Shohei Mizuno, Md Wahiduzzaman, Md Lutfur Rahman, Toshinori Hyodo, Hiroyuki Konishi et al. · 2020 · Cancer Science
  14. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials
    Xinrong Xiang, Qiao He, Yang Ou, Wen Wang, Yu Wu · 2020 · Frontiers in Pharmacology
  15. Massive parallelIGHVgene sequencing reveals a germinal center pathway in origins of human multiple myeloma
    Graeme J. M. Cowan, Nicola J. Weston-Bell, Dean J. Bryant, Anja Seckinger, Dirk Hose, Niklas Zojer, Surinder Singh Sahota · 2015 · Oncotarget
  16. IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM
    Bazarbachi, Abdul Hamid, Avet-Loiseau, Hervé, Szalat, Raphael, Samur, Anil Aktas, Hunter, Zachary, Shammas, Masood, Corre, Jill, Fulciniti, Mariateresa, Anderson, Kenneth C., Parmigiani, Giovanni et al. · 2021 · Blood
  17. Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma
    Deanna J. Fall, Holly A.F. Stessman, Sagar S. Patel, Zohar Sachs, Brian G. Van Ness, Linda Banovic Baughn, Michael Andrew Linden · 2014 · Journal of Cancer
  18. Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing
    Megan J. Fitzpatrick, Valentina Nardi, Aliyah R. Sohani · 2021 · Skeletal Radiology
  19. The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma
    Panagiotis Malamos, Christina Papanikolaou, Maria Gavriatopoulou, Meletios Athanasios Dimopoulos, Evangelos Terpos, Vassilis L. Souliotis · 2024 · International Journal of Molecular Sciences
  20. Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies.
    Dickran Gano Kazandjian, Sham Mailankody, Neha Korde, Ola Landgren · 2014 · PubMed
  21. Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma
    Ankit K. Dutta, Duncan R. Hewett, J. Lynn Fink, John P. Grady, Andrew C.W. Zannettino · 2017 · British Journal of Haematology
  22. The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma
    Mohammad Alzrigat, Helena Jernberg‐Wiklund · 2017 · RNA & DISEASE
  23. Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma
    P. Talley, Andrew Chantry, C. H. Buckle · 2015 · British Medical Bulletin
  24. Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma
    Alessandro Allegra, Roberta Ettari, Vanessa Innao, Alessandra Bitto · 2021 · Cells
  25. SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma
    Tomofumi Yamamoto, Jun Nakayama, Yusuke Yamamoto, Masahiko Kuroda, Yutaka Hattori, Takahiro Ochiya · 2022 · Blood Advances
  26. Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
    Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne · 2022 · Frontiers in Oncology
  27. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
    Larissa Haertle, Santiago Barrio, Umair Munawar, Seungbin Han, Xiang Zhou, Michal Šimíček, Cornelia Vogt, Marietta S. Truger, Rafael Alonso, Maximilian Steinhardt et al. · 2022 · Clinical Cancer Research
  28. Chimeric antigen receptor T-cell therapy for multiple myeloma
    Zehua Wang, Chen Chen, Lei Wang, Yongxu Jia, Yanru Qin · 2022 · Frontiers in Immunology
  29. Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma
    Mengping Chen, Yike Wan, Xin Li, Jing Xiang, Xiaotong Chen, Jinxing Jiang, Xiaofeng Han, Lu Zhong, Fei Xiao, Jia Liu et al. · 2023 · Cell & Bioscience
  30. Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project
    Máire Ní Leathlobhair, Anna Frangou, Ben Kinnersley, Alex J. Cornish, Daniel Chubb, Eszter Lakatos, Prabhu Arumugam, Andreas J Gruber, Philip Law, Avraam Tapinos et al. · 2024 · Nature Communications
  31. Dilemmas in Treating Smoldering Multiple Myeloma
    Inhye E. Ahn, Sham Mailankody, Neha Korde, Ola Landgren · 2014 · Journal of Clinical Oncology
  32. Clonal evolution of esophageal squamous cell carcinoma from normal mucosa to primary tumor and metastases
    Wenqing Yuan, Zhen Liu, Yu Wang, Mengfei Liu, Yaqi Pan, Wanjun Lei, Haijun Yang, Ruiping Xu, Lixin Zhang, Hong Cai et al. · 2019 · Carcinogenesis
  33. Structural and Functional Analyses of the FAM46C/Plk4 Complex
    Hua Chen, Defen Lu, Guijun Shang, Guoming Gao, Xuewu Zhang · 2020 · Structure
  34. Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention
    Samuel Spence McCachren, Kavita M. Dhodapkar, Madhav V. Dhodapkar · 2021 · Frontiers in Immunology
  35. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma
    Saurabh Zanwar, Matthew Ho, Prashant Kapoor, Angela A. Dispenzieri, Martha Q. Lacy, Morie Abraham Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis et al. · 2021 · Leukemia
  36. Breast Cancer Intra-Tumor Heterogeneity: One Tumor, Different Entities
    José Esparza‐López, Elizabeth Escobar-Arriaga, Santos Soto-Germes, Marı́a de Jesús Ibarra-Sánchez · 2017 · Revista de investigaci�n Cl�nica
  37. Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma
    Tuğba Zorlu, Merve Apaydın Kayer, Nazik Okumus, Turgay Ulaş, Mehmet Sinan Dal, Fevzi Altuntaş · 2025 · Diagnostics
  38. Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma
    Stephan Bohl, Laura Katharina Schmalbrock, Imke Bauhuf, Tatjana Meyer, Anna Dolnik, Martin Szyska, Tamara J. Blätte, Sarah Knödler, Linda Röhner, Denise Miller et al. · 2021 · Blood Advances
  39. Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications
    Mengping Chen, Jinxing Jiang, Jian Hou · 2023 · Biomarker Research
  40. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee
    Sarah A. Holstein, Hervé Avet‐Loiseau, Theresa Hahn, Christine M. Ho, Jens G. Lohr, Nikhil C. Munshi, Bruno Paiva, Marcelo C. Pasquini, Joseph Dennis Tario, Saad Z. Usmani et al. · 2017 · Transplantation and Cellular Therapy
  41. The genetic landscape of 5T models for multiple myeloma
    Ken Maes, Bram Boeckx, Philip Vlummens, Kim De Veirman, Eline Menu, Karin Vanderkerken, Diether Lambrechts, Elke De Bruyne · 2018 · Scientific Reports
  42. Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma
    David A. Alagpulinsa, Subodh Kumar, Srikanth Talluri, Purushothama Nanjappa, Leutz Buon, Chandraditya Chakraborty, Mehmet Samur, Raphael Elie Szalat, Masood A. Shammas, Nikhil C. Munshi · 2019 · Blood Advances
  43. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma
    Marcin Jasiński, Grzegorz Władysław Basak, W Wiktor-Jędrzejczak · 2021 · Frontiers in Immunology
  44. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates
    Claudia Buhigas, Anne Yvonne Warren, Wing‐Kit Leung, Hayley C. Whitaker, Hayley J. Luxton, Steve F. C. Hawkins, Jonathan D. Kay, Adam P. Butler, Yaobo Xu, Dan J. Woodcock et al. · 2022 · Molecular Cancer
  45. Multiple myeloma: a model for scientific and clinical progress
    Jesús F. San Miguel · 2014 · Hematology
  46. Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma
    Subodh Kumar, Jiangning Zhao, Srikanth Talluri, Leutz Buon, Shidai Mu, Lakshmi B. Potluri, Chengcheng Liao, Jialan Shi, Chandraditya Chakraborty, Gabriel B. Gonzalez et al. · 2023 · Gastroenterology
  47. The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans
    Francesco Maura, David Glen Coffey, Caleb K. Stein, Esteban Braggio, Bachisio Ziccheddu, Meaghen E. Sharik, Megan T. Du, Yuliza Tafoya Alvarado, Chang-Xin Shi, Yuan Xiao Zhu et al. · 2024 · Nature Communications
  48. Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens
    Dominik Dytfeld, Shaun Rosebeck, Malathi Kandarpa, Anoop M. Mayampurath, Dattatreya Mellacheruvu, Mattina M. Alonge, Lambert C. M. Ngoka, Jagoda K. Jasielec, Paul Gerard Guy Richardson, Samuel L. Volchenboum et al. · 2015 · British Journal of Haematology
  49. Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines
    Susann Weißbach, Sofia Catalina Heredia-Guerrero, Stefanie Barnsteiner, Lukas Großhans, Jochen Bodem, Hanna Starz, Christian Langer, Silke Appenzeller, Stefan Tobias Knop, Torsten Steinbrunn et al. · 2020 · Cancers
  50. Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors
    Zhen Yuan, Xiao Huo, Dezhi Jiang, Mei Yun Yu, Dongyan Cao, Huanwen Wu, Keng Shen, Jiaxin Yang, Ying Zhang, Huimei Zhou et al. · 2020 · The Oncologist
  51. An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics
    Phuc H. Hoang, Alex J. Cornish, Amy L. Sherborne, Daniel Chubb, Scott T. Kimber, Graham Hunter Jackson, Gareth John Morgan, Gordon Cook, Ben Kinnersley, Martin Kaiser et al. · 2020 · Blood Cancer Journal
  52. The Immunity‐malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells
    Tommaso Perini, Maria Materozzi, Enrico Milan · 2021 · FEBS Journal
  53. Common progenitor cells in mature B-cell malignancies
    Michael R. Green, Ash A. Alizadeh · 2014 · Current Opinion in Hematology
  54. Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
    Wolfgang Willenbacher, Andreas Seeber, Normann Steiner, Ella Willenbacher, Zoran Gatalica, Jeffrey J. Swensen, Jeffery Kimbrough, Semir Vranić · 2018 · International Journal of Molecular Sciences
  55. RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
    Michael A. Chapman, Jonathan I. Sive, John C. Ambrose, Claire Roddie, Nicholas Counsell, Anna Lach, Mahnaz Abbasian, Rakesh Popat, Jamie D. Cavenagh, Heather E. Oakervee et al. · 2018 · Blood
  56. Crowd-sourced benchmarking of single-sample tumor subclonal reconstruction
    Adriana Salcedo, Maxime Tarabichi, Alex Buchanan, Shadrielle M. G. Espiritu, Hongjiu Zhang, Kaiyi Zhu, Tai-Hsien Ou Yang, Ignaty Leshchiner, Dimitris Anastassiou, Yuanfang Guan et al. · 2024 · Nature Biotechnology
  57. Time to redefine Myeloma
    Guy Pratt, Stella J. Bowcock, Andrew Chantry, Gordon Cook, Graham Hunter Jackson, Maggie Lai, Eric Low, Nicola J. R. Mulholland, Roger G. Owen, Neil K. Rabin et al. · 2015 · British Journal of Haematology
  58. The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”
    Antonio Giovanni Solimando, Matteo Da Vià, Niccolò Bolli, Torsten Steinbrunn · 2022 · Cancers
  59. Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations
    Saurabh Zanwar, Joseph P. Novak, Wilson I. Gonsalves, Michael Howe, Esteban Braggio, S. Vincent Rajkumar, Moritz Binder, Dragan Jevremović, Surendra Dasari, Shaji Kunnathu Kumar · 2025 · Blood Advances
  60. RNA interference for multiple myeloma therapy: targeting signal transduction pathways
    Jianfeng Guo, Sharon L. McKenna, Michael E O'Dwyer, Mary R. Cahill, Caitríona M. O’Driscoll · 2015 · Expert Opinion on Therapeutic Targets
  61. Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non- MMSET Myeloma Patients
    Shengyang Peter Wu, Ruth M. Pfeiffer, Inhye E. Ahn, Sham Mailankody, Pieter Sonneveld, Mark van Duin, Nikhil C. Munshi, Brian A. Walker, Gareth John Morgan, Ola Landgren · 2016 · Clinical Cancer Research
  62. Next‐generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles
    Bolli, Niccolo, Barcella, Matteo, Salvi, Erika, D'Avila, Francesca, Vendramin, Antonio, De Philippis, Chiara, Munshi, Nikhil C., Avet‐Loiseau, Herve, Campbell, Peter J., Mussetti, Alberto et al. · 2017 · Cancer
  63. Multiparameter Flow Cytometry Identification of Neoplastic Subclones: A New Biomarker in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
    Fabián Tarín, Francisco López-Castaño, Carmen García‐Hernández, Paola Beneit, Héctor Sarmiento, Pablo Manresa Manresa, Olga Alda, Blanca Villarrubia, Margarita Blanes, Javier Bernabéu et al. · 2018 · Acta Haematologica
  64. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient
    Irene Ghobrial, Calixto Hernández Cruz, Alfred L. Garfall, Nina D. Shah, Nikhil C. Munshi, Jonathan L. Kaufman, Lawrence Boise, Gareth John Morgan, Viktor A. Adalsteinsson, Salomon Manier et al. · 2019 · Clinical Lymphoma Myeloma & Leukemia
  65. Risk and Response-Adapted Treatment in Multiple Myeloma
    Titouan Cazaubiel, Olga Mulas, Lydia Montes, Anaïs Schavgoulidze, Hervé Avet‐Loiseau, Jill Corre, Aurore Perrot · 2020 · Cancers
  66. Distinct genomic features across cytolytic subgroups in skin melanoma
    Constantinos Roufas, Ilias Georgakopoulos‐Soares, Apostolos Zaravinos · 2021 · Cancer Immunology Immunotherapy
  67. MCL1 gene co‐expression module stratifies multiple myeloma and predicts response to proteasome inhibitor‐based therapy
    Ayaz Ali Samo, Jiuyi Li, Min Zhou, Yingyu Sun, Yuan Yang, Yunqiu Zhang, Jing Li, Mark van Duin, Xuzhang Lu, Xiaolong Fan · 2018 · Genes Chromosomes and Cancer
  68. New insights from the widening homogeneity perspective to target intratumor heterogeneity
    Mengying Tong, Ziqian Deng, Xiaolong Zhang, Bin He, Meng‐Ying Yang, Wei Cheng, Quentin Liu · 2018 · 癌症：英文版
  69. Gene Expression Profiling Identifies CAV1, CD44, and TFRC as Potential Diagnostic Markers and Therapeutic Targets for Multiple Myeloma
    Awais Ali, Syed Luqman Ali, Waseef Ullah, Asifullah Khan · 2025 · Cell Biochemistry and Biophysics
  70. Targeting the hypoxia pathway in malignant plasma cells by using 17-allylamino-17-demethoxygeldanamycin
    Kinga A. Kocemba‐Pilarczyk, Barbara Ostrowska, S Trojan, Ecce Aslan, Dorota Kusior, Małgorzata Lasota, Claire Lenouvel, Joanna Dulińska-Litewka · 2018 · Acta Biochimica Polonica
  71. Predicting multi-level drug response with gene expression profile in multiple myeloma using hierarchical ordinal regression
    Xinyan Zhang, Bing-Zong Li, Huiying Han, Sha Song, Hongxia Xu, Yating Hong, Nengjun Yi, Wenzhuo Zhuang · 2018 · BMC Cancer
  72. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
    Juan Manuel Rosa-Rosa, Isabel Cuenca, Alejandro Medina, Iria Vázquez, Andrea Sánchez-delaCruz, Natalia Buenache, Ricardo Sánchez, Cristina Jiménez, Laura Rosiñol, Norma Carmen Gutierrez et al. · 2022 · Cancers
  73. Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma
    Jana Jakubı́ková, Dana Cholujová, Gábor Beke, Teru Hideshima, Lubos Klucar, Merav Leiba, Krzysztof Jamroziak, Paul Gerard Guy Richardson, Efstathios Kastritis, David M. Dorfman et al. · 2023 · JCI Insight
  74. Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma
    Antonia Cagnetta, Davide Lovera, Raffaella Grasso, Nicoletta Colombo, Letizia Canepa, Filippo Ballerini, Marino Calvio, Maurizio Miglino, Marco Gobbi, Roberto Massimo Lemoli et al. · 2015 · BioMed Research International
  75. Clinical Grade “SNaPshot” Genetic Mutation Profiling in Multiple Myeloma
    Elizabeth O’Donnell, Anuj Kumar Mahindra, Andrew Jenho Yee, Valentina Nardi, Nicole Birrer, Nora Horick, Darrell R. Borger, Dianne M. Finkelstein, John Iafrate, Noopur S Raje · 2014 · EBioMedicine
  76. Primary plasma cell leukemia 2.0: advances in biology and clinical management
    Antonino Neri, Katia Todoerti, Marta Lionetti, Vittorio Simeon, Marzia Barbieri, Filomena Nozza, Gabriella Vona, Alessandra Pompa, Luca Baldini, Pellegrino Musto · 2016 · Expert Review of Hematology
  77. Novel investigational drugs active as single agents in multiple myeloma
    Mattia D’Agostino, Marco Salvini, Antonio Pierangelo Palumbo, Alessandra Larocca, Francesca Gay · 2017 · Expert Opinion on Investigational Drugs
  78. Circulating microRNAs and Their Role in Multiple Myeloma
    Cinzia Federico, Antonio Sacco, Angelo Belotti, Rossella Ribolla, Valeria Cancelli, Arianna Giacomini, Roberto Ronca, Marco Chiarini, Luisa Imberti, Mirella Marini et al. · 2019 · Non-Coding RNA
  79. Genomic Instability in Multiple Myeloma: A “Non-Coding RNA” Perspective
    Elisa Taìana, Maria Eugenia Gallo Cantafio, Vanessa Katia Favasuli, Cecilia Bandini, Giuseppe Viglietto, Roberto Piva, Antonino Neri, Nicola Amodio · 2021 · Cancers
  80. Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias
    Stefano Testa, Jyoti Kumar, Alex J. Goodell, James L. Zehnder, Kevin Michael Alexander, Surbhi Sidana, Sally Arai, Ronald M. Witteles, Michaela Liedtke · 2022 · Seminars in Oncology
  81. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review
    Charlotte Cosemans, Bénedith Oben, Ingrid Arijs, Annick Daniëls, Jeroen Declercq, Kimberly Vanhees, Guy Froyen, Brigitte Maes, Jeroen Mebis, Jean‐Luc Rummens · 2018 · Clinical Lymphoma Myeloma & Leukemia
  82. The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma
    Cristina Kinahan, Michael A. Mangone, Luigi Scotto, Michele Visentin, Enrica Marchi, Hearn Jay Cho, Owen A. O’Connor · 2020 · Oncotarget
  83. Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma
    Jing Zhao, Xiaoning Wang, Huachao Zhu, Suhua Wei, Hailing Zhang, Le Ma, Pengcheng He · 2022 · Biomolecules
  84. Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature
    José Alberto Nakauma‐González, Maud Rijnders, Minouk T. W. Noordsij, John W.M. Martens, Astrid A.M. van der Veldt, Martijn P. Lolkema, Joost L. Boormans, Harmen J.G. van de Werken · 2024 · Cell Genomics
  85. Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained
    Cassandra J. Vandenberg, Paul Waring, Andreas Strasser, Suzanne Cory · 2014 · Blood
  86. Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
    Pellegrino Musto, Vittorio Montefusco · 2016 · Expert Review of Hematology
  87. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma
    Stefania Oliva, Lorenzo De Paoli, Marina Ruggeri, S Caltagirone, Rossella Troia, Daniela Oddolo, Mattia D’Agostino, Milena Gilestro, Roberto Mina, Elona Saraci et al. · 2021 · Annals of Hematology
  88. EGR1 Addiction in Diffuse Large B-cell Lymphoma
    Shuichi Kimpara, Li Lü, Nguyet Minh Hoang, Fen Zhu, Paul D. Bates, Anusara Daenthanasanmak, Shanxiang Zhang, David T. Yang, Amanda Kelm, Yunxia Liu et al. · 2021 · Molecular Cancer Research
  89. Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome
    Marcella Kaddoura, Moritz Binder, David Dingli, Francis K. Buadi, Martha Q. Lacy, Morie Abraham Gertz, Angela A. Dispenzieri, Prashant Kapoor, Yi L. Hwa, Amie L Fonder et al. · 2022 · American Journal of Hematology
  90. TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells
    Xiaosheng Wu, Patrick R. Blackburn, Renee C. Tschumper, Stephen Carl Ekker, Diane F. Jelinek · 2014 · Blood Cancer Journal
  91. Targeting the Bone Marrow Microenvironment
    Michele Moschetta, Yawara Kawano, Klaus Podar · 2016 · Cancer treatment and research
  92. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
    Yanira Ruiz‐Heredia, Beatriz Sánchez-Vega, Esther Onecha, Santiago Barrio, Rafael Alonso, José Carlos Martínez Ávila, Isabel Cuenca, Xabier Agirre, Esteban Braggio, Miguel-T. Hernández et al. · 2018 · Haematologica
  93. Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma
    Amir Farmanbar, Sanaz Firouzi, Wojciech Makałowski, ROBERT W. KNELLER, Masako Iwanaga, Atae Utsunomiya, Kenta Nakai, Toshiki Watanabe · 2018 · Neoplasia
  94. High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma
    Szabolcs Kosztolányi, Richárd Kiss, Lilit Atanesyan, Ambrus Gángó, Karel de Groot, Maryvonne Steenkamer, Pál Jáksó, András Matolcsy, Béla Kajtár, László Pajor et al. · 2018 · Journal of Molecular Diagnostics
  95. Identification of key genes and construction of microRNA–mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis
    Hongyu Gao, Huihan Wang, Wei Yang · 2017 · International Journal of Hematology
  96. Clinical Significance of Circulating Cell-Free DNA Detection in Multiple Myeloma: A Meta-Analysis
    Xueshi Ye, Wanli Li, Lifei Zhang, Junyao Yu · 2022 · Frontiers in Oncology
  97. RAS/RAF landscape in monoclonal plasma cell conditions
    Anaïs Schavgoulidze, Jill Corre, Mehmet Samur, Céline Mazzotti, Luka Pavageau, Aurore Perrot, Titouan Cazaubiel, Xavier P Leleu, Margaret Macro, Karim Belhadj et al. · 2024 · Blood
  98. Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma
    Matteo Da Vià, Francesca Lazzaroni, Antonio Matera, Alessio Marella, Akihiro Maeda, Claudio De Magistris, Loredana Pettine, Antonio Giovanni Solimando, Vanessa Desantis, Giuseppe M. Peretti et al. · 2025 · Blood
  99. Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
    Jeremy Todd Larsen, Shaji Kunnathu Kumar · 2015 · Rare Cancers and Therapy
  100. Nonsecretory and Light Chain Escape in Patients With Multiple Myeloma
    Urmeel Patel, Joseph J. Drabick, Jozef Malysz, Giampaolo Talamo · 2018 · Clinical Lymphoma Myeloma & Leukemia